Indefinite Delivery Contract HT942525D0009
Award Date
6/1/25
Last Date to Order
5/31/30
Federal Agency
Defense Health Agency
Awardee
Mapp Biopharmaceutical, Inc.
Ultimate Awardee
Not listed
NAICS Category
325413 - In-Vitro Diagnostic Substance Manufacturing
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract, awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Mapp Biopharmaceutical, Inc., a for-profit Subchapter S Corporation, is focused on the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats. The contract, valued at up to $50,097,495, has a period of performance through June 30, 2026 and is a single award with...
This indefinite delivery contract, awarded by the Joint Program Executive Office for Chemical and Biological Defense (part of the U.S. Department of the Army), aims to complete the advanced development of a monoclonal antibody drug product, G03-52-01, to regulatory approval for prophylaxis against aerosolized botulinum neurotoxin A and B serotypes. The prime contractor, Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.), is a technology-focused biomanufacturing...
This indefinite delivery contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian federal agency, to Glaxosmithkline, LLC, a pharmaceutical company, to provide a portfolio of new antibacterial drugs for hospital and biothreat pathogens. The single-award IDC has a ceiling value of $255,851,502.87 and a period of performance through September 30, 2029. The contract aims to procure a range of pharmaceutical products and services from...
Emory University was awarded a single-award indefinite delivery contract by the Defense Health Agency (DHA) to provide services for the generation of monoclonal antibodies (mAbs) for the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The contract has a potential value of $763,502 and runs through September 2025. Under this IDV, Emory has received two firm fixed price delivery orders to date. The first, valued at $309,001, is for clinical trial research services...
This Indefinite Delivery Contract (IDC), awarded by the Defense Health Agency, is for the delivery of monoclonal antibodies to meet the agency's materiel requirements. The contract was awarded to Leinco Technologies, Inc., a self-certified small disadvantaged business and manufacturer of goods, on August 23, 2024 with a total ceiling value of $650,000.00 and a period of performance through September 2, 2029. Leinco Technologies, Inc. has demonstrated expertise in producing high-quality...
This federal contract Indefinite Delivery Vehicle (IDV) was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Biocryst Pharmaceuticals Inc., a for-profit pharmaceutical company based in Durham, North Carolina. The single-award IDV, valued at $90,000,000.00, is for the delivery of drugs and biologicals, with an ultimate completion date of November 2, 2011. The award includes a $22,500,000.00 Firm Fixed Price Delivery Order task order...
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded Amneal Pharmaceuticals of New York, LLC a $3,820,762 Other Transaction Indefinite Delivery Vehicle (IDV) contract. The purpose of this IDV is for the development of an alternative medical countermeasure related to chemical and biological defense programs. As an Other Transaction agreement, this contract was not subject to set-asides. The period of performance for this IDV began on September...
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded Eli Lilly and Company a single award, indefinite delivery contract with a potential value of $2.4 billion to procure monoclonal antibody treatments. Three firm fixed price delivery orders have been issued against this contract vehicle to date, totaling over $1.8 billion, to supply monoclonal antibody products in support of the national interest action code for Coronavirus COVID-19. The initial...
This Other Transaction IDV was awarded on June 13, 2020 by the Defense Advanced Research Projects Agency to Modernatx, Inc. The potential value is $7,852,706. The agreement is to perform optimization work culminating in a Phase I clinical trial of an mRNA construct that encodes a lead SARS-CoV-2 antibody candidate in support of COVID-19 response efforts. Specifically, the prime contractor will develop an optimized mRNA-encoded antibody against the novel SARS-CoV-2 virus. Work will include mRNA...
The provided information describes an Indefinite Delivery Contract (IDC) awarded by the Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response, to the prime contractor Elusys Therapeutics Inc. The contract has a total ceiling value of $69,586,152.55 and a period of performance ending on April 25, 2022. The contract is focused on Research and Development Facilities, with the prime contractor providing a range of biomedical products and...